The association between Akt activation and resistance to hormone therapy in metastatic breast cancer
- 31 March 2006
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (5), 629-635
- https://doi.org/10.1016/j.ejca.2005.11.025
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patientsInternational Journal of Cancer, 2005
- A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast CancerClinical Cancer Research, 2005
- Are all aromatase inhibitors the same? A review of the current evidenceThe Breast, 2004
- Putting the Rap on AktJournal of Clinical Oncology, 2004
- Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathwayOncogene, 2003
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 2003
- Estradiol Rapidly Activates Akt via the ErbB2 Signaling PathwayMolecular Endocrinology, 2003
- Cancer Incidence and Incidence Rates in Japan in 1998: Estimates Based on Data from 12 Population-based Cancer RegistriesJapanese Journal of Clinical Oncology, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998